{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T06:11:30Z","timestamp":1778825490524,"version":"3.51.4"},"reference-count":31,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Juvenile systemic sclerosis (jSSc) is a rare but serious rheumatic disease in children that significantly impacts growth and development. This study aimed to summarize the clinical characteristics and disease patterns of jSSc and to evaluate the treatment response over an 11-year period at our center.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Twenty-one pediatric jSSc patients treated at our center from January 2015 to December 2025 were retrospectively analyzed. Classification was based on the 2013 American College of Rheumatology (ACR)\/European Alliance of Associations for Rheumatology (EULAR) systemic sclerosis classification criteria. Overall disease severity and multiorgan activity were assessed using the Juvenile Systemic Sclerosis Severity Score (J4s; range 0\u201340), while skin involvement was specifically evaluated using the modified Rodnan skin score (mRSS; range 0\u201351). The median follow-up duration was 2.3 years (range 0.5\u20137.2 years). Paired t-tests and Wilcoxon signed-rank tests were used to compare pre- and posttreatment parameters, with p &amp;lt; 0.05 considered statistically significant.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-one patients were enrolled. Skin sclerosis was the most common symptom (100.0%). Antinuclear antibody (ANA) was positive in 16 cases (76.2%), with anti-single-stranded DNA (anti-ssDNA) antibody being the most common specific antibody (23.8%), followed by anti-PM-Scl antibody (19.0%). Glucocorticoids and methotrexate were commonly used as initial therapies. After a median treatment duration of 24 months, overall disease severity (J4s) significantly decreased (5.94 \u00b1 1.66 vs 2.67 \u00b1 2.22, p = 0.003), and skin involvement (mRSS) also improved significantly (10.0 \u00b1 9.21 vs 7.42 \u00b1 8.26, p = 0.008). Fourteen patients received biologic agents, with 11 using tocilizumab. During the follow-up, no deaths or serious adverse events occurred.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>jSSc is a rare and severe multiorgan disease with unique autoantibody profiles in Chinese children. The J4s and mRSS serve as objective assessment tools for evaluating overall disease severity and skin involvement, respectively, and are effective in monitoring treatment response. Early diagnosis and individualized therapy, including the adjunctive use of tocilizumab, may improve clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1818010","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:41:45Z","timestamp":1778823705000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Clinical characteristics, autoantibody profiles, and therapeutic outcomes of juvenile systemic sclerosis: an 11-year single-center experience from China"],"prefix":"10.3389","volume":"17","author":[{"given":"Yating","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjing","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhiyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunfei","family":"An","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology Children\u2019s Hospital of Chongqing Medical University, National Clinical Research Center for Children and Adolescents\u2019 Health and Diseases, Ministry of Education Key Laboratory of Child Development and Disorders","place":["Chongqing, China"]},{"name":"Chongqing Key Laboratory of Child Rare Diseases in Infection and Immunity","place":["Chongqing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa584","article-title":"Consensus-based recommendations for the management of juvenile systemic sclerosis","volume":"60","author":"Foeldvari","year":"2021","journal-title":"Rheumatol (Oxford)"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab738","article-title":"Systemic sclerosis sine scleroderma in children","volume":"61","author":"Zulian","year":"2022","journal-title":"Rheumatol (Oxford)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2018.11.002","article-title":"Contemporary epidemiology of systemic sclerosis: a population-based cohort study in the United Kingdom","volume":"49","author":"Garc\u00eda Rodr\u00edguez","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s12969-024-01043-6","article-title":"An updated overview of juvenile systemic sclerosis in a French cohort","volume":"23","author":"Jacquel","year":"2025","journal-title":"Pediatr Rheumatol Online J"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.2025-0175","article-title":"Clinical and epidemiological features of juvenile-onset systemic sclerosis from a nationwide survey in Japan","volume":"53","author":"Kaneko","year":"2026","journal-title":"J Rheumatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"25","DOI":"10.4078\/jrd.2023.0046","article-title":"Clinical characteristics of juvenile systemic sclerosis in Korea: 31-year single-center study","volume":"31","author":"Jeong","year":"2024","journal-title":"J Rheum Dis"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.55563\/clinexprheumatol\/7ubxxi","article-title":"Clinical profile, long-term follow-up and outcome of juvenile systemic scleroderma: 25 years of clinical experience from North-West India","volume":"131","author":"Jindal","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jpeds.2021.01.068","article-title":"Morbidity and disability in juvenile localized scleroderma: the case for early recognition and systemic immunosuppressive treatment","volume":"234","author":"Li","year":"2021","journal-title":"J Pediatr"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2023.2298354","article-title":"Best clinical practice in the treatment of juvenile systemic sclerosis: expert panel guidance - the result of the International Hamburg Consensus Meeting December 2022","volume":"20","author":"Foeldvari","year":"2024","journal-title":"Expert Rev Clin Immunol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204424","article-title":"2013 classification criteria for systemic sclerosis: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"72","author":"Van Den Hoogen","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/art.34652","article-title":"A preliminary disease severity score for juvenile systemic sclerosis","volume":"64","author":"La Torre","year":"2012","journal-title":"Arthritis Rheum"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/1744666x.2017.1243467","article-title":"Recent advances in the management of juvenile systemic sclerosis","volume":"13","author":"Zulian","year":"2017","journal-title":"Expert Rev Clin Immunol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ker521","article-title":"Access to care for children and young people diagnosed with localized scleroderma or juvenile SSc in the UK","volume":"51","author":"Hawley","year":"2012","journal-title":"Rheumatol (Oxford)"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3390\/ph18050643","article-title":"New challenging systemic therapies for juvenile scleroderma: a comprehensive review","volume":"18","author":"Sassetti","year":"2025","journal-title":"Pharmaceuticals (Basel)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40272-024-00658-2","article-title":"Juvenile dermatomyositis: updates in pathogenesis and biomarkers, current treatment, and emerging targeted therapies","volume":"27","author":"Kim","year":"2025","journal-title":"Paediatr Drugs"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12969-016-0134-0","article-title":"Childhood Arthritis and Rheumatology Research Alliance consensus clinical treatment plans for juvenile dermatomyositis with skin predominant disease","volume":"15","author":"Kim","year":"2017","journal-title":"Pediatr Rheumatol Online J"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehac237","article-title":"2022 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01499-2021","article-title":"ERS\/ATS technical standard on interpretive strategies for routine lung function tests","volume":"60","author":"Stanojevic","year":"2022","journal-title":"Eur Respir J"},{"key":"B19","unstructured":"Integrated addendum to ICH E6(R1): guideline for good clinical practice E6(R2)\n          \n          2016"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-006-0483-z","article-title":"Juvenile onset systemic sclerosis: a single center experience of 23 cases from Asia","volume":"26","author":"Misra","year":"2007","journal-title":"Clin Rheumatol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-020-0386-4","article-title":"Raynaud phenomenon and digital ulcers in systemic sclerosis","volume":"16","author":"Hughes","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keae304","article-title":"Systemic sclerosis sine scleroderma is more aggressive in children than in adults","volume":"63","author":"Tirelli","year":"2024","journal-title":"Rheumatol (Oxford)"},{"key":"B23","article-title":"Childhood onset systemic sclerosis: classification, clinical and serologic features, and survival in comparison with adult onset disease","volume":"33","author":"Scalapino","year":"2006","journal-title":"J Rheumatol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(22)01692-0","article-title":"Systemic sclerosis","volume":"401","author":"Volkmann","year":"2023","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.rdc.2021.07.004","article-title":"Updates in systemic sclerosis treatment and applicability to pediatric scleroderma","volume":"47","author":"Torok","year":"2021","journal-title":"Rheum Dis Clin North Am"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-540-73259-4_7","article-title":"Humanized antihuman IL-6 receptor antibody, tocilizumab","volume":"181","author":"Nishimoto","year":"2008","journal-title":"Handb Exp Pharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04732-z","article-title":"Tocilizumab therapy in juvenile systemic sclerosis: a retrospective single center pilot study","volume":"41","author":"Adrovic","year":"2021","journal-title":"Rheumatol Int"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/s2213-2600(20)30318-0","article-title":"Tocilizumab in systemic sclerosis: a randomized, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Khanna","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204522","article-title":"Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group","volume":"74","author":"Jordan","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keaa193","article-title":"Rituximab for rapidly progressive juvenile systemic sclerosis","volume":"59","author":"Zulian","year":"2020","journal-title":"Rheumatol (Oxford)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11926-020-00910-x","article-title":"Treatment in juvenile scleroderma","volume":"22","author":"Zulian","year":"2020","journal-title":"Curr Rheumatol Rep"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818010\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T05:41:47Z","timestamp":1778823707000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1818010\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":31,"alternative-id":["10.3389\/fimmu.2026.1818010"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1818010","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"article-number":"1818010"}}